Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Voyager Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Voyager Therapeutics, Inc.

VYGR

Voyager Therapeutics, Inc.

About Voyager Therapeutics, Inc.

Voyager Therapeutics is a biotechnology company focused on developing gene therapies for neurological diseases. Utilizing proprietary platforms like TRACER for blood-brain barrier crossing, it advances treatments for Alzheimer’s, Parkinson’s, Friedreich’s ataxia, and other CNS disorders. The company collaborates with industry partners, licensing innovative capsids and antibody technologies to create disease-modifying medicines targeting genetic and protein pathways in the brain.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Voyager Therapeutics, Inc.

1
1
Voyager Therapeutics, Inc. Voyager Therapeutics Reports Q1 2026 Financial Results with Decreased Collaboration Revenue

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Voyager Therapeutics, Inc. Voyager Therapeutics Reports $119.7 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Voyager Therapeutics, Inc. Voyager Therapeutics Reports Significant Revenue Decline and Increased Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Voyager Therapeutics, Inc. Voyager Therapeutics Reports 82% Decline in Collaboration Revenue and Increased Net Losses in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Voyager Therapeutics, Inc. Voyager Therapeutics Reports $31M Net Loss and Decline in Collaboration Revenue in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Voyager Therapeutics, Inc. Voyager Therapeutics Reports $65M Net Loss and $80M Revenue for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Voyager Therapeutics, Inc. Voyager Therapeutics Reports Improved Financials, Increased Collaboration Revenue in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments